Pharmacokinetic and pharmacodynamic studies in man with an antianginal agent ‘Visacor’

1990 ◽  
Vol 11 (3) ◽  
pp. 253-263
Author(s):  
Ian D. Cockshott ◽  
James McAinsh ◽  
Stephanie Norris
Keyword(s):  
Antianginal Agent

scholarly journals Penetration of an antianginal agent, Nicorandil, into mitochondria of rat cardiomyocyte

2000 ◽  
Vol 82 ◽  
pp. 184
Author(s):  
Yoko Tsuchiya ◽  
Michitaka Akima ◽  
Keiji Saito ◽  
Nobuhiko Ishizuka ◽  
Shuzo Matsubara ◽  
...  
Keyword(s):  
Antianginal Agent

scholarly journals Nicorandil-Induced Hyperkalemia in a Uremic Patient

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Hung-Hao Lee ◽  
Po-Chao Hsu ◽  
Tsung-Hsien Lin ◽  
Wen-Ter Lai ◽  
Sheng-Hsiung Sheu
Keyword(s):  
Potassium Channel ◽  
Potassium Ions ◽  
Uremic Patient ◽  
Membrane Hyperpolarization ◽  
Voltage Gated ◽  
Antianginal Agent ◽  
Voltage Gated Calcium Channels ◽  
Detailed Evaluation ◽  
Potassium Channel Activator ◽  
Channel Activator

Nicorandil is an antianginal agent with nitrate-like and ATP-sensitive potassium channel activator properties. After activation of potassium channels, potassium ions are expelled out of the cells, which lead to membrane hyperpolarization, closure of voltage-gated calcium channels, and finally vasodilation. We present a uremic case suffering from repeated junctional bradycardia, especially before hemodialysis. After detailed evaluation, nicorandil was suspected to be the cause of hyperkalemia which induced bradycardia. This case reminds us that physicians should be aware of this potential complication in patients receiving ATP-sensitive potassium channel activator.

scholarly journals Mechanism of action of a novel metabolically active antianginal agent (trimethazidine) delineated by PET

1996 ◽  
Vol 27 (2) ◽  
pp. 132 ◽  
Author(s):  
Freny Vaghalwalla Mody ◽  
Heinrich Schelbert ◽  
Kristine Coyle ◽  
Denis Buxton ◽  
Herbert Hansen ◽  
...  
Keyword(s):  
Mechanism Of Action ◽  
Antianginal Agent

Profile of an Ideal Antianginal Agent

Drugs ◽  
1989 ◽  
Vol 38 (Supplement 2) ◽  
pp. 1-8 ◽  
Author(s):  
Eliot J. Lazar ◽  
William H. Frishman
Keyword(s):  
Antianginal Agent

scholarly journals Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties

Circulation ◽  
2004 ◽  
Vol 110 (8) ◽  
pp. 904-910 ◽  
Author(s):  
Charles Antzelevitch ◽  
Luiz Belardinelli ◽  
Andrew C. Zygmunt ◽  
Alexander Burashnikov ◽  
José M. Di Diego ◽  
...  
Keyword(s):  
Antianginal Agent ◽  
Electrophysiological Effects

Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion

2009 ◽  
Vol 297 (5) ◽  
pp. H1923-H1929 ◽  
Author(s):  
Arvinder K. Dhalla ◽  
Wei-Qun Wang ◽  
Joan Dow ◽  
John C. Shryock ◽  
Luiz Belardinelli ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Ventricular Arrhythmias ◽  
Left Coronary Artery ◽  
Blood Pressure Monitoring ◽  
Ischemia Reperfusion ◽  
Plasma Concentrations ◽  
Median Number ◽  
Vehicle Group ◽  
Pressure Monitoring ◽  
Antianginal Agent

We tested the effect of the antianginal agent ranolazine on ventricular arrhythmias in an ischemic model using two protocols. In protocol 1, anesthetized rats received either vehicle or ranolazine (10 mg/kg, iv bolus) and were subjected to 5 min of left coronary artery (LCA) occlusion and 5 min of reperfusion with electrocardiogram and blood pressure monitoring. In p rotocol 2, rats received either vehicle or three doses of ranolazine (iv bolus followed by infusion) and 20 min of LCA occlusion. With protocol 1, ventricular tachycardia (VT) occurred in 9/12 (75%) vehicle-treated rats and 1/11 (9%) ranolazine-treated rats during reperfusion ( P = 0.003). Sustained VT occurred in 5/12 (42%) vehicle-treated but 0/11 in ranolazine-treated rats ( P = 0.037). The median number of episodes of VT during reperfusion in vehicle and ranolazine groups was 5.5 and 0, respectively ( P = 0.0006); median duration of VT was 22.2 and 0 s in vehicle and ranolazine rats, respectively ( P = 0.0006). With p rotocol 2, mortality in the vehicle group was 42 vs. 17% ( P = 0.371), 10% ( P = 0.162) and 0% ( P = 0.0373) with ranolazine at plasma concentrations of 2, 4, and 8 μM, respectively. Ranolazine significantly reduced the incidence of ventricular fibrillation [67% in controls vs. 42% ( P = 0.414), 30% ( P = 0.198) and 8% ( P = 0.0094) in ranolazine at 2, 4, and 8 μM, respectively]. Median number (2.5 vs. 0; P = 0.0431) of sustained VT episodes, incidence of sustained VT (83 vs. 33%, P = 0.0361), and the duration of VT per animal (159 vs. 19 s; P = 0.0410) were also significantly reduced by ranolazine at 8 μM. Ranolazine markedly reduced ischemia-reperfusion induced ventricular arrhythmias. Ranolazine demonstrated promising anti-arrhythmic properties that warrant further investigation.

Sign in / Sign up

Export Citation Format

Share Document